In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The company is developing an oral and a subcutaneous version of this medicine ... amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Data on the subcutaneous version of amycretin is due ... has compounds that could become a new generation of therapies as Wegovy comes to the end of its patent life in the early 2030s.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

Could the high cost of hugely popular weight loss drugs Ozempic and Wegovy be coming down in the near future? New strain in Calif. Get the USA TODAY app Start the day smarter ☀️ 🐍Year of ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...